Coloplast A/S
CSE:COLO B
Coloplast A/S
Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion.
Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.
Organic Growth: Coloplast reported 8% organic growth in Q1, with both Ostomy Care and Continence Care outgrowing the market.
EBIT Margin: EBIT margin before special items was 27%, slightly down from 28% last year, but in line with management expectations.
Kerecis Momentum: Kerecis delivered 32% growth and was included in the final US reimbursement policy for skin substitutes, though implementation was delayed by two months to April 2025.
Skin Care Divestment: The divestment of the Skin Care business will positively impact group EBIT margin by ~30 basis points but reduce reported revenue for the year by DKK 350 million (~1.5 percentage points).
Product Recalls: Interventional Urology growth was impacted by a voluntary product recall, but sales are resuming and management expects to recover most lost revenue in H2.
Guidance Maintained: Full-year guidance for 8–9% organic revenue growth and ~28% EBIT margin before special items was reaffirmed.
US and Emerging Markets: US delivered double-digit growth, while Emerging Markets were soft due to tough comparisons, with improvement expected later in the year.
Cash Flow & Profit: Free cash flow rose to DKK 1.9 billion (+11% YoY on adjusted basis), and adjusted net profit before special items increased 17%.
You don't have any saved screeners yet
